Omega-3 Plus Low-Dose Aspirin in Smokers With Stage III Periodontitis

This randomized double-blind placebo-controlled clinical trial aims to evaluate the clinical and biochemical effects of omega-3 fatty acids combined with low-dose aspirin as an adjunct to scaling and root planing (SRP) in smoker patients with Stage III periodontitis. The study compares test and control groups regarding periodontal clinical parameters and gingival crevicular fluid interleukin-1 beta (IL-1β) levels Or other inflammatory markers that will be determined later at baseline, 3 months, and 6 months following treatment

Inclusion Criteria: * \- Male or female smokers aged 30 to 50 years. * Diagnosed with Stage III periodontitis according to the 2017 World Workshop classification. * Probing pocket depth (PPD) ≥ 5 mm. * Clinical attachment loss (CAL) ≥ 5 mm. * Presence of at least 20 natural teeth. * Willing and able to provide written informed consent. Exclusion Criteria: * \- Systemic diseases affecting periodontal health. * Pregnancy or lactation. * Periodontal treatment within the previous 6 months. * Use of antibiotics or anti-inflammatory drugs within the previous 6 months. * Allergy or hypersensitivity to omega-3 fatty acids or aspirin. * Long-term anticoagulant therapy. * History of gastric ulcer or bleeding disorders. * Participation in another clinical trial within the previous 3 month